SpayVac-for-Wildlife and BioVaxys jointly have partnered with the Elephant and Wildlife Clinic, Faculty of Veterinary Medicine of Chiang Mai University in Thailand, to test SpayVac, a contraceptive vaccine, in captive Asian elephants, the company announced recently.

“The demonstration that a single-dose injection of SpayVac stimulated consistently elevated antibody titers through at least seven years in the previous trial with captive African elephants further reflects the utility and commercial opportunity in animal species and humans of our liposome-based antigen delivery platform technology,” BioVaxys President and Chief Operating Officer Kenneth Kovan said in a statement.

According to a release, SpayVac utilizes a patented liposome-based antigen delivery platform technology licensed from BioVaxys, which has demonstrated a robust and sustained immune response in several species.